The Latest Breaking News from Edwards

Edwards Lifesciences outlines 2025 growth strategy, emphasizing innovations in TAVR and TMTT therapies, with a projected sales growth of 8%-10% and expanded patient care.

Edwards Lifesciences stock fell Friday after the company said its TAVR segment will face numerous challenges in the fourth quarter.

Looking for some new places to explore and fun things to do in and around Newcastle this year?

Edwards slashed its profit outlook, leading EW stock to plummet Friday amid continued hospital staffing and exchange-rate challenges.

Plus, party time at Modus Merewether, LC Deli, FogHorn Brewery's final pop-up at the footy, Bottomless Bird, and it's your last chance to buy tickets to Thursday night's Four Pillars Gin Dinner at The Edwards.

Elsham Wold Distillery launches two flavours in on-trend ready-to-drink format

The Roundhouse has a new executive chef, meet Paterson Tavern's new owners, and more foodie news.

The growing prevalence of chronic diseases, an increasing elderly population, and rapid adoption of advanced medical technologies are driving the growth of the medical device industry. The industry is expected to witness solid growth over the long term, to the benefit of the stocks of medical device companies Abbott (ABT)…

The sale will not affect the day-to-day running of the venue.